Dermira (DERM) Given “Outperform” Rating at Leerink Swann

Leerink Swann reissued their outperform rating on shares of Dermira (NASDAQ:DERM) in a report published on Thursday.

DERM has been the subject of several other reports. Zacks Investment Research lowered Dermira from a hold rating to a sell rating in a report on Thursday, March 8th. Mizuho reiterated a buy rating on shares of Dermira in a report on Friday, February 23rd. Cantor Fitzgerald set a $45.00 price target on Dermira and gave the company a buy rating in a report on Monday, January 15th. Guggenheim lowered Dermira from a buy rating to a neutral rating in a report on Tuesday, March 6th. Finally, BidaskClub lowered Dermira from a buy rating to a hold rating in a report on Monday, February 5th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $32.71.

How to Become a New Pot Stock Millionaire

Shares of Dermira stock opened at $8.33 on Thursday. The stock has a market capitalization of $365.52, a PE ratio of -1.13 and a beta of 0.86. The company has a debt-to-equity ratio of 1.87, a quick ratio of 5.28 and a current ratio of 5.28. Dermira has a 1-year low of $8.33 and a 1-year high of $36.21.

Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.25) by ($0.09). The firm had revenue of $1.34 million for the quarter, compared to analyst estimates of $1.10 million. Dermira had a negative net margin of 6,678.29% and a negative return on equity of 62.07%. sell-side analysts anticipate that Dermira will post -4.68 earnings per share for the current year.

In related news, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $28.55, for a total value of $85,650.00. Following the completion of the sale, the insider now directly owns 5,802 shares in the company, valued at approximately $165,647.10. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Christopher M. Griffith sold 18,458 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $27.05, for a total value of $499,288.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,758 shares of company stock valued at $728,459. Corporate insiders own 13.30% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of DERM. Millennium Management LLC bought a new position in Dermira in the 4th quarter worth approximately $25,084,000. Franklin Resources Inc. bought a new position in Dermira in the 4th quarter worth approximately $24,820,000. Point72 Asset Management L.P. increased its position in Dermira by 621.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 712,904 shares of the biopharmaceutical company’s stock worth $19,248,000 after buying an additional 614,138 shares during the period. Emerald Advisers Inc. PA bought a new position in Dermira in the 4th quarter worth approximately $14,918,000. Finally, Dimensional Fund Advisors LP bought a new position in Dermira in the 3rd quarter worth approximately $3,107,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Dermira (DERM) Given “Outperform” Rating at Leerink Swann” was reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3297822/dermira-derm-given-outperform-rating-at-leerink-swann.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Barrick Gold  Posts Quarterly  Earnings Results, Misses Estimates By $0.01 EPS
Barrick Gold Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
Moelis & Company  Posts Quarterly  Earnings Results, Beats Expectations By $0.25 EPS
Moelis & Company Posts Quarterly Earnings Results, Beats Expectations By $0.25 EPS
Zacks: Brokerages Expect Apple  to Post $2.69 Earnings Per Share
Zacks: Brokerages Expect Apple to Post $2.69 Earnings Per Share
$0.26 EPS Expected for MoneyGram International Inc  This Quarter
$0.26 EPS Expected for MoneyGram International Inc This Quarter
Analyzing Target  & Its Competitors
Analyzing Target & Its Competitors
Critical Comparison: Ascena Retail Group  vs. Vince
Critical Comparison: Ascena Retail Group vs. Vince


© 2006-2018 Ticker Report. Google+.